Yesterday, Kashiv Pharma, LLC announced its acquisition of the assets of Adello Biologics, LLC, a biotechnology company developing biosimilars. Kashiv will now be known as Kashiv BioSciences, LLC with its headquarters in Bridgewater, New Jersey. It also has research and development and manufacturing facilities in Bridgewater, New Jersey, Piscataway, New Jersey, Chicago, Illinois, and Ahmedabad, India.
In its press release Kashiv stated that “Adello Biologics has been working to develop high-quality, affordable biosimilars for patients worldwide,” and “is advancing a pipeline of complex proteins and monoclonal antibodies with lead candidates in oncology and immunology.” According to the Adello Biologics website, Adello has filgrastim, pegfilgrastim, and adalimumab biosimilars in its pipeline. As we have reported, Adello submitted an aBLA for its filgrastim biosimilar candidate in 2017 and is currently engaged in patent litigation under the BPCIA relating to this product.